GLP-1 receptor agonists slow progression of Parkinson's disease.
- Current status
- ContradictoryEvidence weakening · Parkinsons
- Why
- A phase 2 trial of lixisenatide showed less motor progression at 12 months, but the largest and longest trial (exenatide, phase 3, 96 weeks) found no benefit, and a 2026 meta-analysis of RCTs found no consistent benefit.
- What would change it
- Replication of the lixisenatide result in a larger, longer phase 3 trial with off-medication motor scores.
- Linked studies
- 3 · 1 supports · 2 contradicts
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Supports (1)
- Trial of Lixisenatide in Early Parkinson's DiseaseRandomized trial · 2024 · Study tier 3 · Partial match · Benefit
LixiPark phase 2 (n=156): 3.08-point difference on MDS-UPDRS III at 12 months; 46% nausea.
Contradicts (2)
- Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
Meta-analysis of RCTs: no significant motor or non-motor benefit; more GI adverse events.
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialRandomized trial · 2025 · Study tier 1 · Partial match · Null
Exenatide-PD3 phase 3 (n=194): no difference at 96 weeks.
02History
How this assessment has changed
- ContradictorySep 13, 2026 · Evidence weakening
initial curated status